According to a recent LinkedIn post from Brevel Ltd, the company has been awarded a grant of close to $1 million from the Israel Innovation Authority. The post suggests that these funds are intended to support opening Brevel’s illuminated fermentation platform to external users, including other microalgae strains and plant cell culture applications.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post characterizes this move as positioning Brevel as a “scale up engine” for the next generation of biomanufacturing. For investors, this indicates a potential shift from a solely product-focused model toward a platform-oriented approach that could diversify revenue sources through partnerships, contract development, or scale-up services.
The post also highlights the involvement of a government-backed body, which may be interpreted as an external validation of Brevel’s technology and its relevance to the biomanufacturing and climatetech sectors. Such validation can support Brevel’s credibility in future fundraising, strategic collaborations, and commercial negotiations, particularly with companies pursuing sustainable production solutions.
If executed effectively, opening the platform to third parties could expand Brevel’s addressable market and deepen its role within the broader bio-based manufacturing ecosystem. However, investors may also consider execution risks, including the capital intensity of scale-up, competition from other biomanufacturing platforms, and the need to demonstrate consistent technical performance across diverse biological systems.